Clinical improvement in psoriasis with specific targeting of interleukin-23
By T. Kopp, E. Riedl, C. Bangert, E. Bowman, E. Greisenegger, A. Horowitz, Harald Kittler, W. Blumenschein, T. Mcclanahan, T. Marbury and 8 more. 2015
214 citations recorded by the source corpus.
Subfields: Dermatology, Immunology, Physiology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Dermatology
In Immunology
Citations in the corpus
- Psoriasis Pathogenesis and Treatment (2019, background): “Monoclonal antibodies targeting both the common p40 and the specific p19 subunit of IL-23 have proven to have high clinical efficacy [109].”
- Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12Rβ1 (2017, background): “Indeed, the recent clinical approvals of guselkumab and tildrakizumab, two monoclonal antibodies against IL-23p19 for the treatment of plaque psoriasis (Blauvelt et al., 2017; Kopp et al., 2015; Reich et al., 2017), reflects such efforts for therapeutic differentiation.”